Drug Database
Back to search

Belgium· BE-AMP-SAM157482-00

Aurorix 150 mg

A moclobemide product containing moclobemide, registered in Belgium by Viatris. The same ATC class is registered in 12 of our 19 countries.

ATC N06AG02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAurorix 150 mgATCN06AG02REGISTER NO.BE-AMP-SAM157482-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about moclobemideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Moclobemide is registered in 12 of 19 countries.

Countries holding a registration under ATC N06AG02 (moclobemide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search moclobemide products by name

Moclobemide · ATC N06AG02

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of moclobemide costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.54 in France to $1.38 in Switzerland — a ×2.6 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Moclobemide · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.38
  • FR France$0.54
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Moclobemide
Manufacturer
Viatris
Country
Belgium (BE)
ATC code
N06AG02
ATC class
Moclobemide
Defined daily dose
0.3 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0291963
  • be_apb
    0741355

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

25 interactions on record for moclobemide.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check moclobemide against other medicinesHow interaction checks work

Moclobemide · interactions on record

25 records

25 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Moclobemide in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All moclobemide products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Aurorix
  • Czechia · Aurorix
  • Germany · Aurorix, Moclobemid 1 A Pharma
  • Spain · Manerix
  • Finland · Aurorix
  • France · Moclamine
  • United Kingdom (Northern Ireland) · Manerix, Moclobemide
  • Hungary · Aurorix
  • Ireland · Manerix
  • Netherlands · Moclobemide Sandoz
  • Norway · Aurorix
  • Poland · Aurorix, Mobemid
  • Portugal · Aurorix, Zorix
  • Sweden · Aurorix
  • Slovenia · Aurorix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e91357db-b161-421b-80bc-225089c10df0
GET /v1/drugs/e91357db-b161-421b-80bc-225089c10df0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Aurorix 150 mg",
  "name_fr": "Aurorix 150 mg",
  "name_nl": "Aurorix 150 mg",
  "amp_code": "SAM157482-00",
  "strengths": [
    "150.0000",
    "150.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Moclobemide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Moclobemide",
  "authorisation_numbers": [
    "BE157482"
  ]
}
API referenceMCP serverPlans

See everything about moclobemide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console